Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clorazepate Dipotassium

FDA-approved product (capsule, oral), marketed as Clorazepate Dipotassium, Gen-Xene, Tranxene and 1 more.

Registered studies
4
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Clorazepate Dipotassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clorazepate Dipotassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clorazepate Dipotassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

    NCT04726592 · start 2021-07-08

    Registered record
    Registry ID
    NCT04726592
    Conditions
    Migraine; Migraine Without Aura; Migraine With Aura; Headache
    Interventions
    Clorazepate Dipotassium; Placebo; Ketoprofen; Metoclopramide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-07-08
    Completion
    2024-04-10
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine Without Aura; Migraine With Aura; Headache
    InterventionClorazepate Dipotassium; Placebo; Ketoprofen; Metoclopramide
    PhasePhase 3
    Registry statusTerminated

  • Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

    NCT02323659 · start 2014-06-01

    Registered record
    Registry ID
    NCT02323659
    Conditions
    Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
    Interventions
    Methotrexate; Interferon Alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-06-01
    Completion
    2018-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell, Cutaneous; Mycosis Fungoides
    InterventionMethotrexate; Interferon Alfa-2b
    PhasePhase 4
    Registry statusTerminated

  • Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

    NCT01305707 · start 2009-07

    Registered record
    Registry ID
    NCT01305707
    Conditions
    Depression
    Interventions
    C-ECT; PHARMACOTHERAPY
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-07
    Completion
    2014-07
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionC-ECT; PHARMACOTHERAPY
    PhasePhase 4
    Registry statusTerminated

  • Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions

    NCT00775996 · start 2003-08

    Registered record
    Registry ID
    NCT00775996
    Conditions
    Healthy
    Interventions
    Clorazepate Dipotassium 15mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-08
    Completion
    2003-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionClorazepate Dipotassium 15mg Tablets
    PhaseNot applicable
    Registry statusCompleted